Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

详细摘要

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in…

SHANGHAI & CAMBRIDGE, Mass., November 14, 2026--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease.

"The inclusion of KarXT and VYVGART Hytrulo in the NRDL represents an important milestone for Zai Lab and the patients we serve," said Dr. Yizhe Wang, Zai Lab Operating Partner. "These listings will help broaden access to two important therapies, including KarXT's novel mechanism of action for schizophrenia and the convenience of VYVGART Hytrulo's subcutaneous administration for patients with gMG. Together with the renewal of our other listed products, we are grateful to the National Healthcare Security Administration for its continued support of innovative medicines and remain committed to delivering greater benefit to patients."

The 2026 National Reimbursement Drug List will take effect on January 1, 2027.

*xanomeline and trospium chloride capsules included in the 2026 NRDL covers the following specifications: (I) xanomeline tartrate 50 mg (calculated as C14H23N3OS) and trospium chloride 20 mg per capsule; (II) xanomeline tartrate 100 mg (as C14H23N3OS) and trospium chloride 20 mg per capsule; (III) xanomeline tartrate 125 mg (as C14H23N3OS) and trospium chloride 30 mg per capsule. All are indicated for schizophrenia in adults.

*For AUGTYRO® included in the 2026 NRDL, the reimbursement scope for adult patients with NTRK gene fusion-positive solid tumors is specifically: adult patients diagnosed, by a well-validated testing method, with solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and who meet one of the following conditions: having locally…

Zai…

文章开头，摘自Yahoo Finance。如需阅读全文，请前往媒体网站。